Inferra AI / Company / OMCL
Omnicell, Inc..
OMCL · Health Care
Last earnings Oct 29, 2026
Key results
Total revenuequarter
$311 million
Financial Results Total revenues for the third quarter of 2025 were $311 million, up $28 million, or 10%, from the third quarter of 2024.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Growthquarter
up $28 million
Financial Results Total revenues for the third quarter of 2025 were $311 million, up $28 million, or 10%, from the third quarter of 2024.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Total GAAP net incomequarter
$5 million
Total GAAP net income for the third quarter of 2025 was $5 million, or $0.12 per diluted share.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
GAAP net incomequarter
$9 million
This compares to GAAP net income of $9 million, or $0.19 per diluted share, for the third quarter of 2024.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Net incomequarter
$24 million
Total non-GAAP net income for the third quarter of 2025 was $24 million, or $0.51 per diluted share.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
This compares to non-GAAP net income of $26 million, or $0.56 per diluted share, for the third quarter of 2024.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
AI analysis
Q3 2025 · reported Oct 30, 2025
Based on: Earnings release + parent 8-K — transcript not held
Headline figures
| Metric | Q3 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Total revenue | $311 million | — | — |
| Growth | up $28 million | — | — |
| Total GAAP net income | $5 million | — | — |
| GAAP net income | $9 million | — | — |
| Net income | $24 million | — | — |
Guidance · company-stated
Direction: Raised
“com Omnicell Announces Third Quarter 2025 Financial Results Omnicell delivers strong third quarter financial results Results exceed previously issued third quarter 2025 guidance on all metrics Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas -- October 30, 2025 -- Omnicell, Inc.”
“Given the strength of our performance during the first three quarters of 2025 and visibility into the fourth quarter of the year, we are reaffirming our full year 2025 product bookings and Annual Recurring Revenue outlook and modestly raising our full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Balance Sheet As of September 30, 2025, Omnicell s balance sheet reflected cash and cash equivalents of $180 million, total debt (net of unamortized debt issuance costs) of $167 million, and total assets of $1.9 billion.
During the third quarter of 2025, the Company repaid the remaining principal balance of $175 million of the convertible senior notes that matured on September 15, 2025, as well as repurchased approximately 1,987,000 shares of its common stock for an aggregate purchase price of approximately $62 million.
Event summary
Financial Results Total revenues for the third quarter of 2025 were $311 million, up $28 million, or 10%, from the third quarter of 2024
Based on: Earnings release + parent 8-K — transcript not held
Guidance & outlook
Direction: Raised
Revenue — Raised (“Raises”)
“com Omnicell Announces Third Quarter 2025 Financial Results Omnicell delivers strong third quarter financial results Results exceed previously issued third quarter 2025 guidance on all metrics Raises full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance FORT WORTH, Texas -- October 30, 2025 -- Omnicell, Inc.”
Revenue — Raised (“raising”)
“Given the strength of our performance during the first three quarters of 2025 and visibility into the fourth quarter of the year, we are reaffirming our full year 2025 product bookings and Annual Recurring Revenue outlook and modestly raising our full year 2025 total revenues, non-GAAP EBITDA and non-GAAP EPS guidance.”
Classified from the release's primary full-year outlook statement.
Capital allocation
Balance Sheet As of September 30, 2025, Omnicell s balance sheet reflected cash and cash equivalents of $180 million, total debt (net of unamortized debt issuance costs) of $167 million, and total assets of $1.9 billion.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
During the third quarter of 2025, the Company repaid the remaining principal balance of $175 million of the convertible senior notes that matured on September 15, 2025, as well as repurchased approximately 1,987,000 shares of its common stock for an aggregate purchase price of approximately $62 million.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
As of September 30, 2025, the Company had $350 million of availability under its revolving credit facility with no outstanding balance.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
d) Amortization of debt issuance costs.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Debt issuance costs represent costs associated with the issuance of revolving credit facilities and convertible senior notes.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
We believe free cash flow is important to enable investors to better understand and evaluate our ongoing operating results and allows for greater transparency in the review and understanding of our overall financial, operational, and economic performance, because free cash flow takes into account certain capital expenditures and cash used for software development necessary to operate our business.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Strategy & priorities
Omnicell s Specialty Pharmacy Services business has been awarded the Healthcare Management Certification, Version 3.0 by the Utilization Review Accreditation Commission, the nation s leading independent accreditor of healthcare organizations, known for rigorous standards and focus on continuous improvement.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
These new solutions are focused on driving intelligent outcomes, including delivering a better clinician experience, expanding visibility and oversight for pharmacy enterprise, enhancing safety and accuracy in the IV cleanroom, and transforming outpatient care delivery.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
We present these non-GAAP results and metrics because management considers them to be important supplemental measures of Omnicell s performance and refers to such measures when analyzing Omnicell s strategy and operations.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we believe we should invest in research and development, fund infrastructure growth, and evaluate the effectiveness of marketing strategies.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Risks & headwinds
These forward-looking non-GAAP financial measures do not include certain items, which may be significant, including, but not limited to, unusual gains and losses, costs associated with future restructurings, acquisition-related expenses, and certain tax and litigation outcomes.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Forward-looking statements should be considered in light of these risks and uncertainties.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
As a result of these timing and market uncertainties, the tax effect related to share-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.
SEC original ↗Omnicell, Inc.. — Earnings release (8-K exhibit)EX-99Oct 30, 2025
Earnings deck slides
0 decks with slide viewOmnicell, Inc.. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q3 2026
- 8-KOMCL
Oct 29, 2026
- Q2 2026
- 10-QOMCL
Aug 5, 2026
- 8-KOMCL
Jul 30, 2026
- 8-KOMCL
Jul 1, 2026
- Q1 2026
- 8-KOMCL
May 26, 2026
- 10-QOMCL
May 6, 2026
- 8-KOMCL
Apr 28, 2026
- Q4 2025
- 10-KOMCL
Feb 26, 2026
- 8-KOMCL
Feb 5, 2026
- Q3 2025
- 8-KOMCL
Dec 8, 2025
- 10-QOMCL
Nov 5, 2025
- 8-KOMCL
Oct 30, 2025
- 8-KOMCL
Oct 6, 2025
- Q2 2025
- 8-KOMCL
Aug 25, 2025
- EX-99OMCL
Aug 25, 2025
- 10-QOMCL
Aug 6, 2025
- 8-KOMCL
Jul 31, 2025
- Q1 2025
- 8-KOMCL
Jun 5, 2025
- 8-KOMCL
May 23, 2025
- 8-KOMCL
May 22, 2025
- 10-QOMCL
May 7, 2025
- 8-KOMCL
May 6, 2025
- Q4 2024
- 8-KOMCL
Mar 12, 2025
- 8-KOMCL
Mar 4, 2025
- 10-KOMCL
Feb 27, 2025
- 8-KOMCL
Feb 6, 2025
- Q3 2024
- 8-KOMCL
Nov 25, 2024
- 8-KOMCL
Nov 18, 2024
- 10-QOMCL
Nov 8, 2024
- 8-KOMCL
Oct 30, 2024
- Q2 2024
- 8-KOMCL
Sep 25, 2024
- 10-QOMCL
Aug 6, 2024
Earnings releases
11 documentsPresentations
1 document- Q4 2024
- OMCLDeck
Transcripts
0 documentsNo transcripts for Omnicell, Inc.. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.